Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m(2) with 6 mg/m(2) in the NCRI AML17 Trial

Arecent source data meta-analysis of randomized trials in adults assessing the immunoconjugate gemtuzumab ozogamicin combined with standard chemotherapy in acute myeloid leukemia showed a significant survival benefit in patients without an adverse karyotype. It is not clear whether the optimal dose...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica
Main Authors: Burnett, Alan, Cavenagh, Jamie, Russell, Nigel, Hills, Robert, Kell, Jonathan, Jones, Gail, Nielsen, Ove Juul, Khwaja, Asim, Thomas, Ian, Clark, Richard
Format: Artigo
Language:Inglês
Published: Ferrata Storti Foundation 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013968/
https://ncbi.nlm.nih.gov/pubmed/26921360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.141937
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items